Back to results
US 10,704,100 B2Granted
Biomarkers for heart failure
AssigneeLuxembourg Institute of Health (LIH)
InventorsYvan Devaux, Mélanie Vausort, Lu Zhang
Life of this patent
Estimating the term…
Abstract
The application discloses circRNAs as new biomarkers for the development of heart failure after myocardial infarction; methods for the prediction and diagnosis of heart failure are provided based on measuring said one or more circRNAs; and kits and devices for measuring said circRNAs and/or performing said methods. Further provided are methods for treating patients at risk of heart failure based on the evaluation of said one or more circRNAs.
Claims14
A method for treating a patient at risk of developing heart failure after having suffered from myocardial infarction, said method comprising:
- (a) determining the risk of said patient for developing heart failure by monitoring the expression level of one or more of circRNAs selected from ZNF609_hsa_circ_0000615 (MICRA) (SEQ ID NO:
- 1), SNORD116-19_hsa_circ_0000585 (SEQ ID NO:
- 4), AFF1_hsa_circ_0001423 (SEQ ID NO:
- 8), and SLC8A1_hsa_circ_0000994 (SEQ ID NO:
- 11) in a sample of said patient after said myocardial infarction and comparing said expression level to the expression level of said one or more circRNAs in a reference sample or in a sample of a control patient, wherein a sudden statistically significant deviation of said level is indicative for an increased risk of developing heart failure in said patient and wherein the deviation is statistically significant if the P value is <0.05;
- (b) determining based on (a) that said patient has an increased risk of developing heart failure;
- and
- (c) administering to said patient an effective amount of a drug that treats heart failure.
5 more elements
Dependencies are inferred from the claim text.